Montelucast-Teva (montelukast sodium) coated tablets 10 mg. №28

Description

Montelucast composition

active substance: montelukast sodium;
1 tablet contains montelukast sodium 10.4 mg, which corresponds to montelukast 10.0 mg;
Excipients: microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropylcellulose, croscarmellose sodium, magnesium stearate.

Dosage form
Film-coated tablets.

Pharmacological properties
Montelucast belongs to the group of cystenyl-leukotriene receptor blockers, which play an important role in the development of broncho-obstructive syndrome.
As a result, the drug is effective in the treatment of obstructive diseases that develop in the lower parts of the respiratory system.
Montelukast, which is the main active ingredient of the drug, has the property, when applied, to bind to cystenyl-leukotriene receptors (CysLT1 receptors), which are responsible for the occurrence of bronchospasm, sputum secretion from the bronchi, and other symptoms accompanying obstructive bronchitis.
Capable of inhibiting bronchoconstriction in patients with asthma.
It has the property of arresting the arising bronchospasm at all stages of its development, due to the ability to reduce the body’s response to allergic antigens.
The use of montelukast leads to a decrease in the number of eosinophils in the airways.

Indications
Montelucast is used for the treatment of adults, as a drug for the additional treatment of bronchial asthma in patients with persistent asthma, both mild and moderate, including those who are not sufficiently controlled by inhaled GCS.
Also effective if the patient shows insufficient asthma control with short-acting β-agonists.
Also applicable for:

• symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma;
• prevention of asthma, in which bronchospasm is provoked by physical exertion;
• relieve symptoms of seasonal and perennial allergic rhinitis.

Contraindications
You should not use the specified drug if the patient has had a previous hypersensitivity (allergy) with respect to one of the components that are part of the drug – both basic and auxiliary.

Children
In pediatrics, it is used from the age of 15.

Application during pregnancy and lactation
Treatment of pregnant women is carried out with every possible care, only for serious indications.
Breastfeeding should be suspended during treatment.

Method of administration and dosage
Montelucast is used for asthma and allergic rhinitis (both seasonal and year-round), 1 tablet once a day.
In the treatment of asthma – in the evening, 1-2 hours after the evening meal. For the treatment of allergic rhinitis, the time of taking the drug can be selected on an individual basis.
The therapeutic effect occurs within 24 hours after application.
Do not use the drug concurrently with other medicines that contain montelukast.

Overdose
Overdose with this drug does not cause any particular adverse events. In rare cases, the following were observed:

• drowsiness, psychomotor hyperactivity;
• thirst;
• headache;
• vomiting.

Symptomatic therapy is recommended.

Side effects
Usually the drug is well tolerated. Side effects can occur only in rare cases. In particular, there may be observed:

• anaphylactic reactions, hypersensitivity reactions, including anaphylactic shock;
• upper respiratory tract infections;
• headache, abdominal pain, thirst, nausea, vomiting, dyspepsia;
• increased bleeding;
• sleep disturbances, nightmares, hallucinations, insomnia, irritability, anger, agitation, hostility, depression, disorientation, suicidal thoughts;
• lethargy, dizziness, paresthesia, hypersthesia, palpitations;
• hepatitis, increased levels of hepatic transaminases;
• arthralgia, myalgia, including muscle cramps;
• asthenia / fatigue, discomfort, edema, fever;
• nose bleed.

Storage conditions and periods
Montelucast is able to retain its medicinal properties for 2 years from the date of manufacture indicated on the package.
The drug should be kept out of the reach of children. Storage temperature should not exceed 25 ° C.